Read Time:9 Second
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint. |SUBJECT: Press Release
Happy
0
0 %
Sad
0
0 %
Excited
0
0 %
Sleepy
0
0 %
Angry
0
0 %
Surprise
0
0 %
